OR WAIT null SECS
The new facility, which will be operated by Fujifilm Diosynth Biotechnologies, will provide large-scale cell-culture manufacturing of bulk drug substance with 8 x 20,000-L bioreactors.
Fujifilm Corporation announced on Jan. 7, 2021 that it is investing more than $2 billion into a new large-scale cell-culture production site in the United States to fast-track the growth of its biopharmaceutical contract development and manufacturing organization.
The new facility, which will be operated by Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm Corporation, will provide large-scale cell-culture manufacturing of bulk drug substance with 8 x 20,000-L bioreactors and with the option to add additional 24 x 20,000-L bioreactors, if needed, Fujifilm said in a company press release. Additionally, the site will offer commercial-scale, automated fill-finish and assembly, packaging, and labeling services and is set to be operational in the spring of 2025.
“The United States is the world's biggest market for biopharmaceuticals. I am pleased that through this large investment in the US we are able to support the development and manufacturing of new drugs that can help fulfill unmet medical needs,” said Kenji Sukeno, president of Fujifilm Corporation, in the press release. “Fujifilm will continue to promote human health and support the progress of the healthcare industry by using our cutting-edge technology and advanced facilities to provide a stable supply of high-quality biopharmaceuticals.”
“We are leveraging our strengths in process development and manufacturing for a wide range of biopharmaceuticals such as antibodies, recombinant proteins, gene therapies, and vaccines,” added Martin Meeson, CEO of Fujifilm Diosynth Biotechnologies, in the press release. “We are uniquely placed to support our customer supply chain needs providing end-to-end services from small to large scale bulk drug substance production, through to fill-finish and final packing.”
Source: Fujifilm Corporation